U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06962332) titled 'Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)' on April 30.
Brief Summary: The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Moderate Hepatic Impairment
Intervention:
DRUG: Zanzalintinib
Administered as specified in the treatment arm.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Exelixis
Published by HT Digital Co...